Goyal RK, Zhang J, Davis KL, Sluga-O'Callaghan M, Kaufman PA. Early real-world treatment patterns and clinical outcomes in patients with metastatic breast cancer treated with eribulin after prior immuno-oncology or antibody–drug conjugate therapy. Clin Breast Cancer. 2023 Nov 16;15:855-65. doi: 10.2147/BCTT.S422025
Brufsky A, Mitra D, Davis KL, Nagar SP, McRoy L, Cotter MJ, Stearn V. Treatment patterns and outcomes associated with palbociclib plus letrozole for postmenopausal women with HR-/HER2– advanced breast cancer enrolled in an expanded access program. Clin Breast Cancer. 2019 Oct;19(5):317-25. doi: 10.1016/j.clbc.2019.04.005
Hansen MK, Gammelager H, Jacobsen CJ, Hjortdal VE, Layton JB, Rasmussen BS, Andreasen JJ, Johnsen SP, Christiansen CF. Acute kidney injury and long-term risk of cardiovascular events after cardiac surgery: a population-based cohort study. J Cardiothorac Vasc Anesth. 2015 Jun;29(3):617-25. doi: 10.1053/j.jvca.2014.08.020
Earnshaw SR, Wilson M, Joshi AV. The effect of recombinant activated factor VII in the treatment of intracerebral hemorrhage on health plan budgets. Managed Care Interface. 2007 Jan 1;19(11):39-45.
Earnshaw SR, Wilson MR, Joshi AV. Health plan budget impact analysis of recombinant activated factor VII (rFVIIa) in the treatment of intracerebral hemorrhage. Managed Care Interface. 2006;19(11):39-45.
Earnshaw SR, Candrilli SD, Fernandes AW, Higashi MK. A cost-effectiveness analysis of antibiotic therapy in macrolide-resistant community-acquired pneumonia. Managed Care Interface. 2005 Oct 1;18(10):36-44.